ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP9-22 Timely Filing Denials for COVID-19 Testing and Immunizations
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 09, 2022
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 1751 - 1760 လၢ 3563 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP10-22 Commercial Pharmacy Benefit Exclusion for Basaglar®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP11-22 Commercial Pharmacy Benefit Update – New and Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective April 1, 2022
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP12-22 MHCP Pharmacy Benefit Exclusion for Apretude, Tezspire™ and Vyvgart™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP13-22 Commercial Pharmacy Benefit Exclusion for Apretude, Tezspire™ and Vyvgart™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Substance Use Disorder Concurrent Request Form (PDF)
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Upcoming-policies-effective-April-4-2022.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Credentialing Policy Manual (PDF)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 21, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
contract-request-form.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Non-Participating-Setup-Request-form-January-2022.pdf